Lutetium-177 PSMA Therapy Cost in India

Lutetium-177 PSMA (Prostate-Specific Membrane Antigen) therapy is a targeted radionuclide treatment that delivers radiation directly to prostate cancer cells, minimizing damage to healthy tissues. It has shown promising results in improving survival and quality of life, especially for patients who no longer respond to hormone therapy or chemotherapy.

Lutetium-177 PSMA therapy in India typically costs between $7,000 and $9,000 per cycle, making it significantly more affordable compared to Western countries, where the same therapy can exceed $30,000 per session. This breakthrough nuclear medicine treatment offers new hope to patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted other treatment options.

India has emerged as a top destination for this cutting-edge therapy due to its combination of cost-effectiveness, modern facilities, and access to experienced specialists. Leading oncology centers, under the care of seasoned oncologists like Dr. Ankur Bahl, are at the forefront of delivering personalized and globally recognized care for prostate cancer.

What is Lutetium-177 PSMA Therapy and How Does It Work?

Lutetium-177 PSMA therapy is an advanced form of targeted radionuclide therapy used to treat patients with metastatic castration-resistant prostate cancer (mCRPC). This therapy combines the precision of molecular imaging with the power of internal radiation, delivering treatment directly to prostate cancer cells while sparing healthy tissue.

How It Works

The treatment utilizes a molecule that binds specifically to Prostate-Specific Membrane Antigen (PSMA), a protein present in high concentrations on the surface of prostate cancer cells. This molecule is labeled with Lutetium-177, a radioactive isotope. When injected into the body, the radiolabeled compound seeks out PSMA-expressing cells and binds to them.

Once attached, Lutetium-177 emits beta radiation, which destroys the cancer cells from within. Because it targets only PSMA-positive cells, the therapy minimizes collateral damage to surrounding healthy tissues, a significant advantage over conventional chemotherapy or external beam radiation.

Clinical Effectiveness

Numerous studies, including the landmark VISION trial, have shown that Lutetium-177 PSMA therapy:

• Significantly reduces tumor burden
• Improves progression-free and overall survival
• Enhances quality of life
• Has manageable side effects compared to systemic chemotherapy

This treatment is especially valuable for patients whose disease has spread to bones or lymph nodes and who are no longer responding to hormone therapy or chemotherapy.

Who is a Candidate for Lutetium-177 PSMA Treatment?

Lutetium-177 PSMA therapy is primarily recommended for patients with metastatic castration-resistant prostate cancer (mCRPC). At this stage, the cancer has spread beyond the prostate. It is no longer responding to hormonal therapy. The treatment is typically offered when conventional options like androgen deprivation therapy (ADT), chemotherapy, or androgen receptor blockers have failed to control the disease.

Eligibility Criteria

To be considered for Lutetium-177 PSMA therapy, a patient must meet several clinical and diagnostic criteria:

• Confirmed diagnosis of prostate cancer that is metastatic and hormone-refractory.
• Progressive disease, with evidence of tumor spread on imaging, despite previous treatments.
• Positive PSMA PET scan, showing sufficient uptake of PSMA tracers in cancerous tissues. It is essential for determining whether the cancer cells will respond to the therapy.
• Sufficient kidney, liver, and bone marrow function, as assessed through blood tests, to tolerate the radiopharmaceutical agent.
• No significant PSMA-negative lesions, which could indicate treatment resistance or incomplete targeting.

Ideal Candidates

Ideal candidates for lutetium-177 PSMA therapy are:

• Patients with widespread bone or lymph node metastases.
• Men who have exhausted options like docetaxel, enzalutamide, or abiraterone.
• Those seeking an alternative to cytotoxic chemotherapy with fewer systemic side effects.
• Patients fit enough to receive intravenous radiotherapy and attend scheduled follow-ups.

Who May Not Qualify?

Lutetium-177 PSMA therapy may not be suitable for patients with:

• Minimal or no PSMA uptake on PET scan.
• Severe renal, liver, or bone marrow dysfunction.
• Active infections or comorbid conditions that limit treatment tolerance.
• Prior history of extensive radiation exposure or bone marrow suppression.

Each case is evaluated on an individual basis by a multidisciplinary team. At centers like Fortis Hospital in Gurgaon, oncologists, such as Dr. Ankur Bahl, collaborate with nuclear medicine experts to determine if a patient is a suitable candidate and to design a tailored treatment plan.

What are the Benefits of Lutetium Therapy for Advanced Prostate Cancer?

Lutetium-177 PSMA therapy offers a groundbreaking approach to treating metastatic prostate cancer, particularly in patients who have limited options left. Unlike traditional therapies that affect both healthy and cancerous cells, this targeted treatment selectively destroys PSMA-positive cancer cells, improving outcomes while minimizing toxicity.

• Targeted Tumor Destruction: One of the most essential benefits is precision targeting. The therapy binds explicitly to cells expressing PSMA, a protein found in high density on prostate cancer cells. It minimizes radiation exposure to surrounding healthy organs and tissues.
• Delays Disease Progression: Clinical trials such as the VISION trial and TheraP study have demonstrated that Lutetium-177 PSMA therapy significantly improves progression-free survival. It also delays the need for additional chemotherapy and reduces PSA (Prostate-Specific Antigen) levels in most patients. These outcomes are critical in late-stage disease, where controlling cancer growth can directly improve both survival and comfort.
• Better Tolerability Compared to Chemotherapy: Unlike chemotherapy, which can cause severe fatigue, hair loss, nausea, and infections, Lutetium therapy is better tolerated. Most patients experience only mild and manageable side effects, such as dry mouth, mild fatigue, or temporary drops in blood counts.
• Effective Even in Advanced, Treatment-Resistant Cases: This therapy is beneficial in castration-resistant prostate cancer (CRPC), where hormonal therapy has failed. Many patients respond well to Lutetium even after multiple previous treatments, making it one of the few options available for such advanced stages.
• Improved Quality of Life: Patients undergoing this treatment often report pain relief (especially in cases of bone metastases), improved appetite and energy, and better emotional well-being.
• Outpatient or Short Hospital Stay: Most patients receive this therapy in a day-care setting or undergo a short hospital admission, thereby reducing disruption to their daily lives. Recovery is quick, with patients resuming normal activities within a few days.

Step-by-Step Overview of the Lutetium-177 PSMA Procedure

Specialized cancer centers in India follow internationally approved protocols to deliver Lutetium-177 PSMA therapy safely and effectively. Here's how the process unfolds:

Step 1: Undergo a Pre-Treatment Evaluation

Your medical team will begin with a thorough evaluation to determine if you're eligible for treatment. They will:

• Perform a PSMA PET-CT scan to confirm that your tumors express PSMA.
• Order blood tests to check kidney, liver, and bone marrow function.
• Review your treatment history and overall health status.

If your test results meet the safety criteria, the team will schedule you for therapy.

Step 2: Meet for Treatment Planning and Counseling

You will meet with a nuclear medicine specialist and an oncologist to discuss:

• How many treatment cycles do you typically need (3 to 6)?
• What benefits and side effects to expect?
• Safety guidelines for radiation exposure after each session.
• A detailed cost estimate and timeline for your therapy.

The hospital will assist you in preparing both medically and logistically for each cycle.

Step 3: Prepare the Radiopharmaceutical

Certified nuclear medicine staff will prepare the Lutetium-177 PSMA compound in a specialized lab. They:

• Combine Lutetium-177 with a PSMA-binding molecule.
• Test the compound for purity, dose accuracy, and sterility.
• Ensure it's ready for use within the isotope's active timeframe.

Hospitals follow strict radiation safety protocols throughout this step.

Step 4: Receive the Treatment via IV Infusion

On the day of treatment:

• You'll enter a radiation-shielded treatment room.
• The care team will insert an IV line and slowly infuse the Lutetium-177 PSMA compound over 30 to 60 minutes.
• Hospital nursing staff will monitor your vital signs and comfort throughout the infusion.
• Most patients are discharged within 1 to 2 days, in accordance with radiation safety guidelines.

Step 5: Follow Post-Treatment Safety and Monitoring

After discharge:

• You will receive instructions to limit close contact with pregnant women and young children for a few days.
• Your doctors will schedule regular blood tests and PSA level checks.
• You will attend follow-up scans after a few cycles to assess your treatment response.

Step 6: Continue with Additional Treatment Cycles

If you respond well and show no significant side effects:

• You'll return every 6 to 8 weeks for the next cycle.
• Doctors will adjust your care plan based on how your body and cancer respond.
• You may undergo 3 to 6 cycles, depending on your condition and treatment goals.

Throughout the entire process, the hospital's international patient team will assist you in coordinating appointments, accommodations, and travel.

Lutetium-177 PSMA Therapy Cost in India

India offers one of the most affordable options for Lutetium-177 PSMA therapy without compromising on medical quality or safety. The average cost of Lutetium-177 PSMA therapy in India ranges from $7,000 to $9,000 (₹6.5 to ₹10 lakh) per cycle, depending on the hospital, location, and the number of treatment sessions required.

Patients typically need 3 to 6 cycles for optimal results. While the total treatment cost varies from case to case, most patients complete their full course for $24,000 to $60,000, which is a fraction of what leading hospitals charge in the United States, UK, or Australia.

What's Included in the Cost?

Hospitals offer all-inclusive packages that often cover:

• PSMA PET-CT scan before therapy
• Consultation with oncologists and nuclear medicine specialists
• Preparation and administration of the Lutetium-177 radiopharmaceutical
• Radiation-protected room and hospital stay (1–2 days)
• Post-treatment blood tests and monitoring
• Discharge summary and radiation safety counseling
• Follow-up planning and support for future cycles

Many hospitals also offer international patient coordinators to assist with scheduling, logistics, and billing.

Customized Treatment Plans

Not every patient requires the same number of treatment cycles or dosage. Your oncologist will customize the treatment plan based on:

• PSMA expression levels on the PET scan
• Extent of metastasis
• Overall health and blood count status
• Prior treatment history

As a result, your total cost may vary slightly depending on your personalized medical needs.

Response Rates and Survival Outcomes of Lutetium-177 PSMA Therapy

Lutetium-177 PSMA therapy has gained global recognition for its effectiveness in treating mCRPC, a stage at which many other treatments often lose efficacy. Multiple international trials and real-world studies have confirmed its ability to improve tumor control, alleviate pain, and improve survival outcomes.

How Well Does Lutetium-177 PSMA Therapy Work?

The landmark VISION trial (2021), a global phase III study, evaluated over 800 patients with mCRPC who had already undergone hormonal and chemotherapy treatments. Results from this and other clinical studies reveal:

• More than 70% of patients show a decline in PSA levels, often within 2–3 weeks after the first cycle.
• Approximately 30% to 50% of prostate cancer patients experience a greater than 50% reduction in PSA, indicating a strong tumor response.
• Imaging studies (e.g., PSMA PET-CT) show partial or complete metabolic responses in a large portion of patients after 3–4 cycles.

Survival Benefits Backed by Data

According to the VISION trial:

• Overall survival improved from 11.3 months to 15.3 months in patients receiving Lutetium-177 PSMA therapy.
• Radiographic progression-free survival nearly doubled, from 3.4 months to 8.7 months.
• Patients also reported significant pain relief, improved physical functioning, and better quality of life scores.

Another major study, the TheraP trial (2021, Australia), compared Lu-177 PSMA therapy with cabazitaxel (a chemotherapy drug). It found:

• Sixty-six percent of patients in the Lu-177 group achieved a PSA decline of over 50% compared to 37% in the chemo group.
• Fewer severe side effects and hospitalizations occurred in the Lu-177 group.

Real-World Observations from India

In Indian cancer centers such as Fortis Gurgaon, oncologists and nuclear medicine experts report outcomes similar to global benchmarks. Patients often see:

• Symptom relief after 1–2 cycles
• Decreased bone pain and improved appetite
• A drop in PSA levels even in heavily pre-treated individuals
• Improved emotional well-being and mobility

Side Effects and How to Manage Them

While Lutetium-177 PSMA therapy is generally well tolerated, like any form of cancer treatment, it may cause specific side effects. Fortunately, most of these are mild and manageable with timely medical support. Understanding potential reactions helps patients mentally and physically prepare before starting therapy.

Common Side Effects

The most frequently observed side effects include:

• Dry mouth (xerostomia) occurs because the salivary glands also express PSMA and may receive some radiation during treatment. Patients often report dryness, especially after multiple cycles.
• Fatigue: Mild tiredness or reduced energy is common after therapy, usually lasting a few days. It's generally self-limiting and resolves with rest and hydration.
• Nausea and appetite loss: A small number of patients may experience nausea or reduced appetite, typically within the first 24–48 hours after infusion.
• Bone marrow suppression: In rare cases, the therapy may cause a reduction in blood counts (anemia, leukopenia, or thrombocytopenia), especially in patients who already have bone metastases. This is usually monitored with routine blood tests.
• Mild abdominal discomfort or changes in bowel habits: Some patients report constipation or bloating, which typically settle without intervention.

Rare or Serious Side Effects

While uncommon, the following may occur in select patients:

• Kidney dysfunction: Lutetium is filtered by the kidneys, so individuals with pre-existing kidney disease require careful monitoring. Adequate hydration before and after the infusion reduces the risk.
• Liver enzyme changes: Temporary elevations may be seen in some patients but rarely require treatment.
• Radiation exposure risks: These are minimal, as the therapy is targeted and delivered under strict safety protocols.

Managing and Minimizing Side Effects

To reduce or manage side effects, doctors typically advise the following:

• Drink plenty of fluids before and after therapy to help support kidney function and clearance.
• Use artificial saliva or sugar-free lozenges to ease dry mouth.
• Rest adequately after each cycle and avoid strenuous activity for 24–48 hours.
• Monitor blood counts regularly, especially if your cancer has spread to bones.
• Report any unusual symptoms to your treating physician promptly for early intervention and treatment.

What are the Factors Influencing the Cost of Lutetium-177 PSMA Treatment?

The cost of Lutetium-177 PSMA therapy in India varies depending on several key medical and logistical factors. Understanding these variables helps patients and caregivers plan their treatment budget more accurately.

• Number of Treatment Cycles: Most patients require between 3 and 6 cycles, administered at 6–8 week intervals. Each additional Lu-177 PSMA cycle adds to the overall cost. Patients who show a better early response may require fewer sessions, while others may need more.
• PSMA PET Scan and Pre-Treatment Investigations: Before starting therapy, you must undergo a PSMA PET-CT scan to confirm the presence of PSMA-positive cancer cells. The cost of this scan and other routine investigations (e.g., blood tests, kidney function tests) is typically billed separately, unless they are included in a package.
• Choice of Hospital and Location: Top-tier hospitals in metro cities like Delhi, Mumbai, and Bangalore may charge slightly higher due to premium infrastructure and advanced nuclear medicine departments. However, they also offer better safety, experienced teams, and more streamlined international services.
• Doctor's Expertise and Reputation: Specialists with extensive experience in nuclear oncology may charge slightly higher professional fees. However, this investment often ensures better outcomes, safety, and care coordination.
• Room Type and Hospital Stay: Most patients stay for 1 to 2 days in radiation-protected rooms. Costs vary based on the room type (standard vs. deluxe), hospital policy, and additional nursing or isolation services during this time.
• Post-Treatment Care and Follow-Up: You may require supportive medications, laboratory tests, and ongoing monitoring after each session. While many hospitals include these services in the treatment package, some may charge separately, especially for outpatient services or teleconsultations after discharge.

Cost Comparison: India vs Other Countries

One of the key reasons international patients travel to India for Lutetium-177 PSMA therapy is the significant cost advantage. Despite offering high-quality care and internationally accredited hospitals, India's treatment prices remain much lower than those in the West.

Lutetium-177 PSMA Therapy Cost by Country (Per Cycle)

Note: These costs are estimates and may vary based on individual hospitals, exchange rates, and package inclusions.

In India, you can receive the same treatment at one-third the price, making it not just affordable but also accessible to patients who may otherwise delay or skip this life-prolonging therapy.

Why Choose India for PSMA Therapy?

India has rapidly become a global destination for advanced cancer care, and Lutetium-177 PSMA therapy is no exception. Patients from across Asia, Africa, Europe, and the Middle East are choosing Indian hospitals not only for their affordability, but also for the clinical excellence and compassionate care they receive.

• Internationally Accredited Hospitals: Many leading hospitals in India are NABH- and JCI-accredited, which ensures they meet rigorous international standards for patient safety, quality of care, and infection control. Centers like Fortis Memorial Research Institute are fully equipped with nuclear medicine departments and radiopharmaceutical labs.
• Expert Oncologists and Nuclear Medicine Teams: India is home to some of the most experienced oncologists and nuclear medicine specialists. Oncologists like Dr. Ankur Bahl bring deep expertise in handling complex prostate cancer cases and work closely with nuclear medicine teams to customize treatment protocols for each patient.
• Cost-Effective and Transparent Pricing: Indian hospitals offer upfront, package-based pricing, helping patients avoid unexpected expenses. Even with multiple treatment cycles, the total cost remains a fraction of what Western countries charge, with no compromise in safety or effectiveness.
• Minimal Waiting Times: Unlike in many public healthcare systems abroad, Indian hospitals typically have no waiting period for consultations, imaging, or therapy scheduling. This is especially critical for patients with advanced disease who need timely intervention.
• Supportive International Patient Programs: Most leading hospitals have dedicated international desks that handle everything from visa assistance and airport transfers to translation services and post-treatment teleconsultations. It ensures a seamless and stress-free experience for patients traveling from abroad.
• Access to Advanced Diagnostics: India offers advanced imaging technologies like PSMA PET-CT, Ga-68 scans, and post-therapy SPECT imaging, which are essential for planning, administering, and monitoring Lutetium-177 PSMA therapy. These facilities are readily available in major cancer centers.

Services for International Patients

Hospitals offering Lutetium-177 PSMA therapy in India provide a comprehensive range of services to make treatment easier, smoother, and more accessible for patients traveling from abroad. These support services help alleviate stress, allowing patients to focus on recovery and healing.

• Personalized medical coordination is provided from the initial inquiry to the final follow-up, ensuring that patients receive individualized guidance throughout their treatment journey.
• Dedicated case managers and translators are available to help bridge any language or cultural gaps, making it easier to communicate with the medical team and understand instructions.
• Assistance with medical visa invitations is provided, allowing patients to obtain the required documentation quickly and with minimal hassle.
• Airport pickup and hospital transfers are arranged for patients and their companions, offering a safe and convenient way to reach the treatment center.
• Help with accommodation near the hospital is offered, including hotel or guest house bookings tailored to the patient's budget and preferences.
• Flexible appointment scheduling ensures that all scans, consultations, and therapy sessions are booked in advance, reducing waiting time and facilitating efficient care coordination.
• Daily support during hospitalization includes addressing dietary preferences, providing interpreters, and maintaining constant updates to family members.
• Post-treatment follow-up care and reports are shared digitally, allowing patients to continue their care or monitoring with their local physicians after returning home.
• Financial guidance and transparent billing are provided to help patients understand cost estimates, payment options, and insurance-related queries (if applicable).

These patient-centered services make India one of the most welcoming and efficient destinations for international cancer care, particularly for advanced and emerging treatments such as Lutetium-177 PSMA therapy.

Patient Testimonials

David M., 67 – United Kingdom

"After exhausting my options in the UK, I turned to India for PSMA therapy. I was amazed at how quickly Fortis Gurgaon arranged everything. Dr. Ankur Bahl's team was thorough and empathetic. The treatment cost me less than a third of what it would back home, and the results have been promising. I'm back home now, pain-free and hopeful."

Hausa K., 72 – Nigeria

"I couldn't afford the high cost of Lutetium therapy in Europe. A friend recommended Fortis Hospital in India. The international team handled my visa and logistics, and Dr. Bahl explained the entire process in simple terms. I've completed 4 cycles and feel stronger each day. I am very thankful for the care and dignity I received."

Paul R., 69 – Australia

"Getting timely PSMA therapy in Australia was nearly impossible due to long waitlists. India turned out to be a blessing. From airport pickup to discharge, everything was professionally handled. The doctors were experienced, and the hospital maintained high standards of hygiene and comfort. I would recommend Fortis and Dr. Bahl to anyone in need."

Ahmed H., 64 – Oman

"My father was diagnosed with advanced prostate cancer. We flew to India within a week thanks to the fast coordination. The cost was clear from the start, and the facilities exceeded our expectations. Dr. Ankur Bahl provided compassionate care throughout. We're seeing great progress, and the treatment was truly life-extending."